The National Institute for Clinical Excellence (NICE) has rejected yet another life saving drug which will now not be available to patients on the NHS.
Coming less than a week after NICE refused the Liver Cancer drug Nexavar, NICE have now confirmed they will not fund Avastin used in the treatment of Metacystic Bowel Cancer, that is where the disease has spread around the body.
Avastin costs about £1,800 per month and has been shown to shrink tumours in 78% of patients when used in conjunction with chemotherapy and Oxaliplatin. If Avastin were licensed for use on the NHS it could potentially extend the lives of around 6000 patients per year. The UK is now virtually the only country in the developed world not to provide Avastin for Bowel Cancer free to patients in the state healthcare system. The drug which is available in countries such as Australia, Canada and most of Europe does not fit NICE’s “quality adjusted life year” (QALY) as the drug is still too expensive.
The producer of Avastin, Roche, is still in talks with NICE over access to the drug. Roche have set up a Patient Access Scheme which will reduce the cost of Avastin by capping its costs at 12 months and offer free Oxaliplantin.
On a personal note, I have acted for a 26 year old patient who suffered from terminal Metacystic Bowel Cancer. The Primary Care Trust in question refused to fund Avastin as it had not been approved by NICE and the PCT refused to treat the patient as “exceptional”. Avastin, which has been shown to typically increase survival from 19.9 months to 21.3 months was not given in this case and unfortunately the patient died before we were able to take the case to the High Court.
It seems that NICE are taking a harder line on the licensing of new treatments for rarer Cancers which has the direct side effect of bringing more agony and heartache to patients and their families.

